Literature DB >> 2170481

Itraconazole therapy in aspergillosis: study in 49 patients.

B Dupont1.   

Abstract

Itraconazole, 200 to 400 mg once daily, was administered to 49 patients with different types of aspergillosis: pulmonary aspergilloma (14 patients), chronic necrotizing pulmonary aspergillosis (14), and invasive aspergillosis (21). Itraconazole was prescribed alone or in combination or after treatment with amphotericin B and flucytosine. Of 14 aspergilloma patients, 2 were cured and 8 had symptomatic improvement. In chronic necrotizing pulmonary aspergillosis, 7 of 14 patients were cured and 6 improved significantly. In invasive aspergillosis treatment failed in 6 patients and 15 were cured. Itraconazole can be an alternative to amphotericin B in the treatment of invasive aspergillosis and chronic necrotizing pulmonary aspergillosis. In aspergilloma itraconazole may be useful in inoperable cases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2170481     DOI: 10.1016/0190-9622(90)70263-h

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  22 in total

Review 1.  Triazole antifungal agents in invasive fungal infections: a comparative review.

Authors:  Cornelia Lass-Flörl
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 2.  Antifungal treatment strategy in leukemia patients.

Authors:  T Büchner; N Roos
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

Review 3.  Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature.

Authors:  Tahuanty A Pena; Ayman O Soubani; Lobelia Samavati
Journal:  Lung       Date:  2011-02-13       Impact factor: 2.584

4.  Persistent pulmonary lesion in a patient with rheumatoid arthritis.

Authors:  F Buttgereit; K Künzel; H J Tietz; K Sajkiewicz; K Gellert; F Hiepe; G R Burmester
Journal:  Ann Rheum Dis       Date:  1994-12       Impact factor: 19.103

5.  Management of pulmonary aspergillosis in AIDS: an emerging clinical problem.

Authors:  J J Keating; T Rogers; M Petrou; J D Cartledge; D Woodrow; M Nelson; D A Hawkins; B G Gazzard
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

Review 6.  Efficacy of acute phase and maintenance therapy with itraconazole in an AIDS patient with sporotrichosis.

Authors:  F Bolao; D Podzamczer; M Ventin; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-07       Impact factor: 3.267

7.  Sternal osteomyelitis caused by Aspergillus fumigatus in a patient with previously treated Hodgkin's disease.

Authors:  D Allen; S Ng; K Beaton; D Taussig
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

8.  New in vitro assay based on glucose consumption for determining intraconazole and amphotericin B activities against Aspergillus fumigatus.

Authors:  J C Garrigues; G Cadet de Fontenay; M D Linas; M Lagente; J P Seguela
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

9.  Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.

Authors:  J Berenguer; N M Ali; M C Allende; J Lee; K Garrett; S Battaglia; S C Piscitelli; M G Rinaldi; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 10.  Diagnosis and treatment of invasive fungal infections in cancer patients.

Authors:  P Martino; C Girmenia
Journal:  Support Care Cancer       Date:  1993-09       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.